MDGL$430.360.31%-1.34
After Hours: 433.06+2.70 +0.63%
Madrigal Pharmaceuticals Inc (MDGL)
Date: 2026-10-30 16:00O: 431.55H: 437.80L: 425.00C: 430.36Vol: 251.5k
Madrigal Pharmaceuticals Inc stock is traded at $430.36, with a volume of 251,450. It is down -0.31% in the last 24 hours and down -14.60% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Previous Close:
$431.70
Open:
$431.55
24h Volume:
251,450
Relative Volume:
0.91
Market Cap:
$9.94B
Revenue:
$1.13B
Net Income/Loss:
-$309.44M
P/E Ratio:
-
EPS:
-$12.80
Net Cash Flow:
-$275.41M
1W Performance:
-0.89%
1M Performance:
-14.60%
6M Performance:
-16.82%
1Y Performance:
+0.66%
1-Day Range:
$425.00$437.80
1-Week Range:
$425.00$445.66
52-Week Range:
$399.00$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
404-380-9263Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, USACompare MDGL vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL Madrigal Pharmaceuticals Inc | $430.36 | $9.94B | $1.13B | -$309.44M | -$275.41M | -$12.80 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Madrigal Pharmaceuticals Inc Stock (MDGL) Insider Trading
- Sibold William JohnSep 11 '26President and CEO
- Transaction
- Sale
- Cost
- $542.39
- #Shares
- 5,221
- Value ($)
- 2,831,801
- #Shares Total
- 197,746
- WILLIAM SIBOLDSep 11 '26Director
- Transaction
- Proposed Sale
- Cost
- $533.12
- #Shares
- 5,221
- Value ($)
- 2,783,420
- #Shares Total
- 0
- William John SiboldSep 09 '26Officer and Director
- Transaction
- Proposed Sale
- Cost
- $534.16
- #Shares
- 6,362
- Value ($)
- 3,398,326
- #Shares Total
- 0
- Sibold William JohnSep 09 '26President and CEO
- Transaction
- Sale
- Cost
- $535.59
- #Shares
- 6,362
- Value ($)
- 3,407,397
- #Shares Total
- 202,967
- Kelley Shannon TAug 17 '26General Counsel
- Transaction
- Sale
- Cost
- $514.97
- #Shares
- 664
- Value ($)
- 341,940
- #Shares Total
- 11,474
- Shannon KelleyAug 17 '26Officer
- Transaction
- Proposed Sale
- Cost
- $507.56
- #Shares
- 664
- Value ($)
- 337,020
- #Shares Total
- 0
- Sibold William JohnJul 20 '26President and CEO
- Transaction
- Sale
- Cost
- $547.30
- #Shares
- 2,500
- Value ($)
- 1,368,253
- #Shares Total
- 209,329
- William SiboldJul 20 '26Officer and Director
- Transaction
- Proposed Sale
- Cost
- $553.48
- #Shares
- 2,500
- Value ($)
- 1,383,700
- #Shares Total
- 0
- Soergel DavidJun 01 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $495.74
- #Shares
- 1,042
- Value ($)
- 516,561
- #Shares Total
- 10,033
- DAVID SOERGELJun 01 '26Officer
- Transaction
- Proposed Sale
- Cost
- $497.27
- #Shares
- 1,042
- Value ($)
- 518,155
- #Shares Total
- 0
